Focus:
Eli Lilly has completed the acquisition of all outstanding shares of Loxo Oncology in a deal valued at approximately $8bn, boosting its oncology portfolio with precision medicines to potentially treat...
US precision medicine company Sarepta Therapeutics has announced the US Food and Drug Administration (FDA) has accepted its new drug application (NDA) for its Duchenne muscular dystrophy (DMD) drug Golodirsen...
As a result of promising data from its Phase Ib/II KEYNOTE-365 trial, Merck has announced three new Phase III trials into the safety and efficacy of Keytruda (pembrolizumab) for patients...
Gene therapy company Passage Bio has launched in the US with $115.5m series A funding to develop AAV-delivered therapies for the treatment of rare monogenic central nervous system (CNS) disorders.
India-based Glenmark Pharmaceuticals is set to spin-off its innovation business into a new company in the US to increase focus on innovation and advance its pipeline towards commercialisation.
Researchers at Addiction and Mental Health (CAMH) in Canada have developed new therapeutic small molecules that could potentially reverse memory loss caused due to depression and ageing.
South Korea-based SK Biopharmaceuticals and Swiss Arvelle Therapeutics have signed an exclusive licensing agreement to develop and commercialise SK Biopharmaceuticals’ cenobamate in Europe.
Canada-based AbCellera has announced it has signed a multi-year, multi-target agreement with Novartis under which its antibody discovery technology will be leveraged by the Swiss pharma giant for up to...
Researchers at the Wyss Institute at Harvard University have created ‘decoy’ platelets that could potentially reduce blood clots, as well as prevent cancer from spreading.
Eisai has submitted an application to the European Medicines Agency (EMA) seeking approval for the use of its Fycompa (perampanel) medicine to treat paediatric patients suffering with epilepsy.
Go Top
